MAPT and Parkinson disease: For example, selectivity evaluation could be enhanced by a panel of cases that includes 1) PD with dementia containing representative levels of α-syn pathology but no Aβ and tau pathology, 2) AD containing representative levels of Aβ and tau but no α-syn pathology, and 3) PSP/CBD containing only tau pathology.